Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

Optimization of the Anti-Inflammatory Treatment of Asthma Patients Through Exhaled NO Measurements for Increased Asthma-Related Quality of Life in Primary Health Care (NOAK)

The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma

Inclusion Criteria:

• Age 18-64
• Clinical diagnosis of Asthma
• Glucocorticoid treatment > 6 months.
• Verified Allergy
• Read and speak Swedish

Exclusion Criteria:

• Smoking
• Current regular treatment with long-acting beta2-agonist
• Treatment with Singulair only or in combination with glucocorticoids
• Taking part in other research study
• Pregnancy or breast-feeding
• Unstable Asthma